Lars Huber

2.4k total citations
45 papers, 1.8k citations indexed

About

Lars Huber is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Lars Huber has authored 45 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 13 papers in Surgery and 10 papers in Molecular Biology. Recurrent topics in Lars Huber's work include Pulmonary Hypertension Research and Treatments (22 papers), Transplantation: Methods and Outcomes (11 papers) and MicroRNA in disease regulation (7 papers). Lars Huber is often cited by papers focused on Pulmonary Hypertension Research and Treatments (22 papers), Transplantation: Methods and Outcomes (11 papers) and MicroRNA in disease regulation (7 papers). Lars Huber collaborates with scholars based in Switzerland, Germany and United States. Lars Huber's co-authors include Steffen Gay, Rudolf Speich, Silvia Ulrich, Renate E. Gay, Matthias Brock, Oliver Distler, Jörg H. W. Distler, Beat A. Michel, Michelle Trenkmann and David S. Pisetsky and has published in prestigious journals such as Journal of Biological Chemistry, CHEST Journal and European Heart Journal.

In The Last Decade

Lars Huber

44 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Huber Switzerland	22	751	639	393	288	268	45	1.8k
Matthias Brock Switzerland	18	672 0.9×	1.0k 1.6×	865 2.2×	124 0.4×	200 0.7×	39	1.9k
Yukinari Masuda Japan	21	384 0.5×	579 0.9×	158 0.4×	232 0.8×	119 0.4×	52	1.7k
Yuki Morimoto Japan	25	695 0.9×	592 0.9×	381 1.0×	271 0.9×	201 0.8×	89	2.0k
Matthias C. Kugler United States	15	1.2k 1.6×	908 1.4×	371 0.9×	320 1.1×	123 0.5×	26	2.4k
Kurt R. Weiss United States	23	445 0.6×	770 1.2×	323 0.8×	306 1.1×	82 0.3×	79	1.8k
Hiroshi Nanjo Japan	25	794 1.1×	624 1.0×	253 0.6×	616 2.1×	97 0.4×	156	2.1k
Matthias Werner Germany	15	1.1k 1.5×	477 0.7×	330 0.8×	311 1.1×	101 0.4×	27	2.3k
Axelle Caudrillier United States	14	530 0.7×	771 1.2×	267 0.7×	350 1.2×	99 0.4×	15	2.6k
Jasper Koerts Netherlands	17	204 0.3×	826 1.3×	284 0.7×	317 1.1×	92 0.3×	28	1.6k
Christina Bergmann Germany	18	424 0.6×	808 1.3×	127 0.3×	205 0.7×	493 1.8×	53	1.9k

Countries citing papers authored by Lars Huber

Since Specialization

Citations

This map shows the geographic impact of Lars Huber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Huber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Huber more than expected).

Fields of papers citing papers by Lars Huber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Huber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Huber. The network helps show where Lars Huber may publish in the future.

Co-authorship network of co-authors of Lars Huber

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Huber. A scholar is included among the top collaborators of Lars Huber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Huber. Lars Huber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huber, Lars, et al.. (2018). First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial – preliminary results. Swiss Medical Weekly. 148(708). w14593–w14593. 13 indexed citations

Benden, Christian, et al.. (2017). Therapy options for chronic lung allograft dysfunction–bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review. The Journal of Heart and Lung Transplantation. 36(9). 921–933. 48 indexed citations

Haider, Thomas, Johannes Vogel, Louise Østergaard, et al.. (2017). Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells in hypoxia-induced pulmonary hypertension. Basic Research in Cardiology. 112(3). 30–30. 21 indexed citations

Hasler, Elisabeth, Stéphanie Saxer, Lars Huber, et al.. (2016). Prevalence of Anxiety and Depression in Pulmonary Hypertension and Changes during Therapy. Respiration. 91(5). 359–366. 25 indexed citations

Saxer, Stéphanie, Mona Lichtblau, Elisabeth Hasler, et al.. (2016). Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. European Respiratory Journal. 48(6). 1658–1667. 52 indexed citations

Brock, Matthias, Thomas Rechsteiner, Malcolm Kohler, Daniel Franzen, & Lars Huber. (2015). Kinetics of microRNA Expression in Bronchoalveolar Lavage Fluid Samples. Lung. 193(3). 381–385. 5 indexed citations

Brock, Matthias, Thomas Haider, Johannes Vogel, et al.. (2015). The hypoxia-induced microRNA-130a controls pulmonary smooth muscle cell proliferation by directly targeting CDKN1A. The International Journal of Biochemistry & Cell Biology. 61. 129–137. 46 indexed citations

Rechsteiner, Thomas, Esther I. Schwarz, Matthias Brock, Lars Huber, & Malcolm Kohler. (2014). The micro-RNA hsa-miR-502-3p is down-regulated in the plasma of obstructive sleep apnea patients after 2 weeks of continuous positive airway pressure therapy withdrawal: Data from a randomized controlled trial. European Respiratory Journal. 44(Suppl 58). P2201–P2201. 1 indexed citations

Huber, Lars, et al.. (2014). 5 years follow-up of lung transplant recipients undergoing extracorporal photophoresis. European Respiratory Journal. 44(Suppl 58). P3324–P3324. 1 indexed citations

10.

Müller-Mottet, Séverine, Elisabeth Hasler, Rudolf Speich, et al.. (2014). Long-term Effect of Vasodilator Therapy in Pulmonary Hypertension due to COPD: A Retrospective Analysis. Lung. 192(6). 987–995. 16 indexed citations

11.

Speich, Rudolf, et al.. (2013). Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension. International Journal of Clinical Pharmacy. 36(2). 256–260. 5 indexed citations

12.

Hildenbrand, Florian F., et al.. (2012). A low resting heart rate at diagnosis predicts favourable long-term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational study. Respiratory Research. 13(1). 76–76. 18 indexed citations

13.

Brock, Matthias, Michelle Trenkmann, Colin C. Schwarzwald, et al.. (2012). AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. European Heart Journal. 35(45). 3203–3211. 127 indexed citations

14.

Brock, Matthias, Michelle Trenkmann, Renate E. Gay, et al.. (2011). MicroRNA-18a Enhances the Interleukin-6-mediated Production of the Acute-phase Proteins Fibrinogen and Haptoglobin in Human Hepatocytes. Journal of Biological Chemistry. 286(46). 40142–40150. 72 indexed citations

15.

Ulrich, Silvia, Lars Huber, Manuel Fischler, et al.. (2010). Platelet Serotonin Content and Transpulmonary Platelet Serotonin Gradient in Patients with Pulmonary Hypertension. Respiration. 81(3). 211–216. 19 indexed citations

16.

Ulrich, Silvia, Martin Hersberger, Manuel Fischler, et al.. (2009). Bone Mineral Density and Secondary Hyperparathyroidism in Pulmonary Hypertension. The Open Respiratory Medicine Journal. 3(1). 53–60. 17 indexed citations

17.

Guiducci, Serena, Jörg H. W. Distler, Astrid Jüngel, et al.. (2008). The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis & Rheumatism. 58(9). 2845–2853. 80 indexed citations

18.

Ulrich, Silvia, Laima Tarasevičienė-Stewart, Lars Huber, Rudolf Speich, & Norbert F. Voelkel. (2008). Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respiratory Research. 9(1). 20–20. 47 indexed citations

19.

Drees, Philipp, Anke Eckardt, Renate E. Gay, Steffen Gay, & Lars Huber. (2007). Mechanisms of Disease: molecular insights into aseptic loosening of orthopedic implants. Nature Clinical Practice Rheumatology. 3(3). 165–171. 85 indexed citations

20.

Distler, Jörg H. W., Astrid Jüngel, Lars Huber, et al.. (2006). Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis & Rheumatism. 56(1). 311–322. 299 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact